Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
DSG3/1-CAART is being developed to treat mucocutaneous pemphigus vulgaris (mcPV), a B cell-mediated autoimmune disease that causes blistering of the skin and mucous membranes. mcPV is caused by autoantibodies that attack the cell adhesion proteins DSG3 and DSG1.
DSG3/1-CAART is designed to selectively target and kill the B cells that express the pathogenic autoantibodies while preserving the healthy B cells critical to immune function. We anticipate that much of what we learn from our DSG3-CAART program, including clinical trial design in the DesCAARTesTM trial, will inform and potentially accelerate the development of DSG3/1-CAART.
Current treatments for mcPV call for corticosteroids and generalized immune suppression. This therapeutic approach can be temporarily effective but carries a substantial risk of disease recurrence, severe infection, and even death. We are currently developing a new candidate therapy that targets only pathogenic B cells and their autoantibodies, and may, with minimal side effects, achieve durable remission of this disease.
PV is a chronic, life-threatening autoimmune disease characterized by delamination, or separation of the layers of the skin and/or mucous membranes. Autoantibodies directed to DSG3 and/or DSG1, which are proteins expressed in desmosomes, the rivets between epithelial cells, are responsible for disease. When these desmosomes fail, erosions and blisters appear on the skin and mucosa, increasing the patient’s susceptibility to potentially fatal infections.
The pathogenic DSG3 and DSG1 autoantibodies are produced by a small number of aberrant B cells, which express the same DSG3 and DSG1 autoantibodies on their surface. These DSG-specific autoantibodies are widely considered both necessary and sufficient to cause PV.
PV has two major subtypes:
Symptoms of mcPV include blisters on the skin as well as the mucous membranes, including the mouth, nose, throat, and genitals, causing high levels of pain and impairing the patient’s ability to eat, drink, or function normally.
